Elsevier

Neuropharmacology

Volume 23, Issue 12, Part 2, December 1984, Pages 1561-1569
Neuropharmacology

Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides

https://doi.org/10.1016/0028-3908(84)90100-XGet rights and content

Abstract

In patients with Alzheimer-type dementia, in addition to the well-known losses of cholinergic neurones, there is evidence of degeneration of the noradrenergic and serotonergic innervation of the cerebral cortex. While noradrenergic and cholinergic receptors are preserved there is a loss of serotonin S1 and S2 receptors, particularly in the temporal lobe. The loss of serotonin S2 receptors may occur at an early stage of the disease and, in temporal and frontal cortex, is correlated with the loss of somatostatin immunoreactivity. In patients dying in hospital with depression, and in individuals committing suicide, there are no consistent changes in monoamine metabolites. Noradrenergic, serotonergic, and other neurotransmitter receptors were found to be unchanged, although there was a moderate decrease in imipramine binding in a small group (n = 6) of subjects with a history of depression, who had committed suicide.

References (54)

  • C.M.B. Pare et al.

    5-Hydroxytryptamine, noradrenaline and dopamine in the brain stem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coalgas poisoning

    Lancet

    (1969)
  • R.C.A. Pearson et al.

    Retrograde cell degeneration in the basal nucleus in monkey and man

    Brain Res.

    (1983)
  • E.K. Perry et al.

    Necropsy evidence of central cholinergic deficits in senile dementia

    Lancet

    (1977)
  • R.H. Perry et al.

    Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease

    Neurosci. Lett.

    (1982)
  • M.N. Rossor et al.

    The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes

    Neurosci. Lett.

    (1982)
  • M. Stanley et al.

    Increased serotonin-2 binding sites in the frontal cortex of suicide victims

    Lancet

    (1983)
  • M. Stanley et al.

    Suicide and serotonin receptors

    Lancet

    (1984)
  • B.E. Tomlinson et al.

    Observations on the brains of demented old people

    J. neurol. Sci.

    (1970)
  • R.W.P. Achor et al.

    Hypertension treated with Rauwolfia Serpentina (whole root) and with reserpine

    J. Am. med. Ass.

    (1955)
  • R. Adolfsson et al.

    Changes in brain catecholamines in patients with dementia of Alzheimer-type

    Br. J. Psychiat.

    (1979)
  • J.S. Benton et al.

    Alzheimer's disease as a disorder of the isodendritic core

    Lancet

    (1982)
  • A. Bertler

    Effect of reserpine on the storage of catecholamines in brain and other tissues

    Acta physiol. scand.

    (1961)
  • D.M. Bowen et al.

    Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

    Brain

    (1976)
  • D.M. Bowen et al.

    Accelerated ageing or selective neuronal loss as an important cause of dementia

    Lancet

    (1979)
  • E. Cochran et al.

    Regional serotonin levels in brain: a comparison of depressive suicides and alcoholic suicides with controls

    Biol. Psychiat.

    (1976)
  • A.J. Coppen

    The biochemistry of affective disorders

    Br. J. Psychiat.

    (1967)
  • A.J. Cross et al.

    Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease

    Br. med. J.

    (1981)
  • Cited by (287)

    • Evaluation of 5-HT<inf>2A</inf> and mGlu<inf>2/3</inf> receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment

      2014, Neuropharmacology
      Citation Excerpt :

      Moreover, higher postmortem prefrontal 5-HT2R binding has also been shown to correlate with lifetime aggression in suicide (Oquendo et al., 2006). Nevertheless, other studies have not found significant differences in prefrontal cortex 5-HT2AR density neither between suicide and non-suicide subjects (Oquendo et al., 2006) nor between depressed suicide subjects and controls (Owen et al., 1983; Crow et al., 1984; Cheetham et al., 1988; Arranz et al., 1994; Lowther et al., 1994; Stockmeier et al., 1997; Rosel et al., 2000; Underwood et al., 2012). Additionally, we have previously reported that prefrontal cortex [3H]ketanserin binding did not differ in a group of suicide victims with a variety of psychiatric disorders as compared to controls (Muguruza et al., 2013).

    • Dysregulated 5-HT<inf>2A</inf> receptor binding in postmortem frontal cortex of schizophrenic subjects

      2013, European Neuropsychopharmacology
      Citation Excerpt :

      In this study, there were no differences in [3H]ketanserin binding to the 5-HT2AR in a group of suicide victims with psychiatric disorders such as dysthymic disorder, alcoholism, and anorexia nervosa, among others. Similarly, previous work has shown that [3H]ketanserin binding is unaffected in postmortem frontal cortex of suicide victims with major depression (Owen et al., 1983; Crow et al., 1984; Cheetham et al., 1988; Arranz et al., 1994; Lowther et al., 1994; Stockmeier et al., 1997; Rosel et al., 2000). Few studies using [3H]ketanserin reported that the 5-HT2AR is altered in suicide victims without psychiatric diagnosis (Gross-Isseroff et al., 1990a; Turecki et al., 1999). [

    View all citing articles on Scopus
    View full text